Category archive


Comparing Blood-Thinners for Atrial Fibrillation

Apixaban [Eliquis] scores highest of all the NOACs, “on the balance of efficacy, safety and cost.” Pharmacy News December 5, 2017 Which NOAC scores highest for atrial fibrillation? New ranking may help guide decision-making Apixaban is the most efficient non-vitamin K oral anticoagulant (NOAC) for treating atrial fibrillation, according to the results of a meta-analysis including 95,000 patients from 23 randomised controlled trial. There’s already a large body of evidence that NOACs are at least as effective as warfarin and… Keep Reading

FDA blood thinners

FDA: Atrial Fibrillation and New Oral Anticoagulant Drugs

From the US Food and Drug Administration October 2016 Ellis F. Unger, M.D. More than 3 million Americans have atrial fibrillation, a problem with the electrical system of the heart that causes an irregular heart rhythm. Atrial fibrillation can produce palpitations, shortness of breath, lightheadedness, weakness, and chest pain, or may occur without symptoms. The main concern, however, is that atrial fibrillation can lead to the formation of blood clots in the heart, which can travel to the brain and… Keep Reading

antidote to pradaxa's side effects heartcurrenets

Antidote for Pradaxa’s Blood Thinning Side Effects

Idarucizumab, given by injection, appears to stop the effect of dabigatran and allow the blood to clot. Harvard Health Letter –February, 2016 There’s encouraging news for people who take dabigatran (Pradaxa), a newer type of blood thinner that’s had a rare side effect of uncontrolled bleeding during surgery or accidents. In October 2015, the FDA approved an antidote called idarucizumab (Praxbind), which may be able to reverse dabigatran’s blood-thinning effects. Dabigatran was approved by the FDA in 2010 and welcomed… Keep Reading

blood thinners blood cells heartcurrents

Reversing the Effects of the New Anti-Clotting Drugs

Though catastrophic bleeding from the novel oral anticoagulants is extremely rare, the availability of antidotes reassures health care providers, patients, and their families. It changes the psychology of prescribing and tilts the balance more strongly toward the novel agents. Harvard Health Blog –December 9, 2018\6 –Samuel Z. Goldhaber, MD The oral anticoagulant warfarin (Coumadin) became available for prescription in 1954. This anti-clotting drug commanded national attention when President Dwight Eisenhower received the drug as part of his treatment following a… Keep Reading

bunch of pills heart medicine compliance heartcurrents

Issues in Heart Medication Adherence

Less than half of heart patients take their prescriptions as directed. American College of Cardiology Medication Adherence Remains Challenging for Heart Patients –January 2017– With less than half of heart patients taking their prescriptions as directed, increasing medication adherence is critical to improving public health, based on a recent review published in the Journal of the American College of Cardiology. Each year, heart disease accounts for roughly 125,000 preventable deaths—many of which result from patients failing to take life-saving medication. In… Keep Reading

ekg of atrial fibrillation heartcurrents

Xarelto Approved for Treatment of Atrial Fibrillation (2011)

Source: Xarelto Approved by the FDA for Atrial Fibrillation Stroke Prevention November 4, 2011 By Mellanie True Hills Summary: The FDA has approved a second alternative to warfarin, Xarelto (rivaroxaban), for stroke prevention in atrial fibrillation. The U.S. Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those who have non-valvular atrial fibrillation (afib that is not related to heart valve problems). Xarelto becomes the second oral alternative to warfarin and is considered a good… Keep Reading

Go to Top